EDGEMOND JAMES

The transaction cadence — 452 separate filings — is consistent with regular, scheduled selling. The per-transaction size is modest relative to the total, which is typical of either periodic 10b5-1 executions or manual sales timed around earnings blackout periods. The absence of any buy signal anywhere in the record removes the most common bullish-insider pattern.

UTHR's size as a biotech name — a mid-cap pulmonary-hypertension specialist with a small commercial base and a development pipeline — makes the sell volume notable in context. 434K shares represents a meaningful fraction of the company's public float, and sustained distribution of this magnitude over multiple years gradually transfers insider economic interest to public-market holders.